Failure of omalizumab for treatment of severe adult atopic dermatitis
Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months.
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 2005-08, Vol.53 (2), p.338-340 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 340 |
|---|---|
| container_issue | 2 |
| container_start_page | 338 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 53 |
| creator | Krathen, Richard A. Hsu, Sylvia |
| description | Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months. |
| doi_str_mv | 10.1016/j.jaad.2005.02.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68038501</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S019096220500681X</els_id><sourcerecordid>68038501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-20f09275bdd49b5dccc7866ceb88294a99eae88f5b7e1a557aec4821d290af023</originalsourceid><addsrcrecordid>eNp9kEtLLDEQRoNc0fHxB1xIb667bivpRxJwc5HxAYIbXYfqpBoydE-PSVrw_nq7mQF3rmpR5_uqOIxdcSg48OZ2U2wQXSEA6gJEAbw6YisOWuaNVPIPWwHXkOtGiFN2FuMGAHRVyhN2yhsQnJf1iq0f0PdToGzssnHA3v-fBmyzbgxZCoRpoG1adpE-aabQTX3KMI07bzNHYcDkk48X7LjDPtLlYZ6z94f12_1T_vL6-Hz_7yW3papSLqADLWTdOlfptnbWWqmaxlKrlNAVak1ISnV1K4ljXUskWynBndCAHYjynN3se3dh_JgoJjP4aKnvcUvjFE2joFQ18BkUe9CGMcZAndkFP2D4MhzMIs9szCLPLPIMCDPLm0PXh_apHcj9RA62ZuDvAcBose8Cbq2PP5zkUJbVcv1uz9Hs4tNTMNF62lpyPpBNxo3-tz--AZaFjSY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68038501</pqid></control><display><type>article</type><title>Failure of omalizumab for treatment of severe adult atopic dermatitis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Krathen, Richard A. ; Hsu, Sylvia</creator><creatorcontrib>Krathen, Richard A. ; Hsu, Sylvia</creatorcontrib><description>Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2005.02.014</identifier><identifier>PMID: 16021135</identifier><identifier>CODEN: JAADDB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adult ; Age Factors ; Allergic diseases ; Antibodies, Anti-Idiotypic ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Biological and medical sciences ; Dermatitis, Atopic - drug therapy ; Dermatology ; Female ; Humans ; Immunopathology ; Male ; Medical sciences ; Middle Aged ; Omalizumab ; Severity of Illness Index ; Skin allergic diseases. Stinging insect allergies ; Treatment Failure</subject><ispartof>Journal of the American Academy of Dermatology, 2005-08, Vol.53 (2), p.338-340</ispartof><rights>2005 American Academy of Dermatology, Inc.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-20f09275bdd49b5dccc7866ceb88294a99eae88f5b7e1a557aec4821d290af023</citedby><cites>FETCH-LOGICAL-c384t-20f09275bdd49b5dccc7866ceb88294a99eae88f5b7e1a557aec4821d290af023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaad.2005.02.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17103341$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16021135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krathen, Richard A.</creatorcontrib><creatorcontrib>Hsu, Sylvia</creatorcontrib><title>Failure of omalizumab for treatment of severe adult atopic dermatitis</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Allergic diseases</subject><subject>Antibodies, Anti-Idiotypic</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Biological and medical sciences</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Omalizumab</subject><subject>Severity of Illness Index</subject><subject>Skin allergic diseases. Stinging insect allergies</subject><subject>Treatment Failure</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLLDEQRoNc0fHxB1xIb667bivpRxJwc5HxAYIbXYfqpBoydE-PSVrw_nq7mQF3rmpR5_uqOIxdcSg48OZ2U2wQXSEA6gJEAbw6YisOWuaNVPIPWwHXkOtGiFN2FuMGAHRVyhN2yhsQnJf1iq0f0PdToGzssnHA3v-fBmyzbgxZCoRpoG1adpE-aabQTX3KMI07bzNHYcDkk48X7LjDPtLlYZ6z94f12_1T_vL6-Hz_7yW3papSLqADLWTdOlfptnbWWqmaxlKrlNAVak1ISnV1K4ljXUskWynBndCAHYjynN3se3dh_JgoJjP4aKnvcUvjFE2joFQ18BkUe9CGMcZAndkFP2D4MhzMIs9szCLPLPIMCDPLm0PXh_apHcj9RA62ZuDvAcBose8Cbq2PP5zkUJbVcv1uz9Hs4tNTMNF62lpyPpBNxo3-tz--AZaFjSY</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Krathen, Richard A.</creator><creator>Hsu, Sylvia</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050801</creationdate><title>Failure of omalizumab for treatment of severe adult atopic dermatitis</title><author>Krathen, Richard A. ; Hsu, Sylvia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-20f09275bdd49b5dccc7866ceb88294a99eae88f5b7e1a557aec4821d290af023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Allergic diseases</topic><topic>Antibodies, Anti-Idiotypic</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Biological and medical sciences</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Omalizumab</topic><topic>Severity of Illness Index</topic><topic>Skin allergic diseases. Stinging insect allergies</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krathen, Richard A.</creatorcontrib><creatorcontrib>Hsu, Sylvia</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krathen, Richard A.</au><au>Hsu, Sylvia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Failure of omalizumab for treatment of severe adult atopic dermatitis</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>53</volume><issue>2</issue><spage>338</spage><epage>340</epage><pages>338-340</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><coden>JAADDB</coden><abstract>Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>16021135</pmid><doi>10.1016/j.jaad.2005.02.014</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 2005-08, Vol.53 (2), p.338-340 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68038501 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Age Factors Allergic diseases Antibodies, Anti-Idiotypic Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Dermatitis, Atopic - drug therapy Dermatology Female Humans Immunopathology Male Medical sciences Middle Aged Omalizumab Severity of Illness Index Skin allergic diseases. Stinging insect allergies Treatment Failure |
| title | Failure of omalizumab for treatment of severe adult atopic dermatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A32%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Failure%20of%20omalizumab%20for%20treatment%20of%20severe%20adult%20atopic%20dermatitis&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Krathen,%20Richard%20A.&rft.date=2005-08-01&rft.volume=53&rft.issue=2&rft.spage=338&rft.epage=340&rft.pages=338-340&rft.issn=0190-9622&rft.eissn=1097-6787&rft.coden=JAADDB&rft_id=info:doi/10.1016/j.jaad.2005.02.014&rft_dat=%3Cproquest_cross%3E68038501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68038501&rft_id=info:pmid/16021135&rft_els_id=S019096220500681X&rfr_iscdi=true |